An isoniazid analogue promotes Mycobacterium tuberculosis- nanoparticle interactions and enhances bacterial killing by macrophages

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2259-2267

  De Faria, Tatiany J ^a   Roman, Mariane ^a   De Souza, Nicole M ^a   De Vecchi, Rodrigo ^a   De Assis, João Vitor ^b   Dos Santos, Ana Lúcia Gomes ^a   Bechtold, Ivan H ^a   Winter, Nathalie ^c   Soares, Maurilio José ^d   Silva, Luciano Paulino ^e   De Almeida, Mauro V ^b   Báfica, André ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c UR1282   (France)

^d INSTITUTO CARLOS CHAGAS   (Brazil)

^e EMBRAPA RECURSOS GENÉTICOS E BIOTECNOLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; ISONIAZID DERIVATIVE; JVA; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HYDROPHOBICITY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISONIAZID; LACTIC ACID; MACROPHAGES; MICE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, CONFOCAL; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; POLYGLYCOLIC ACID; TUBERCULOSIS, PULMONARY;

EID: 84860185958     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05993-11     Document Type: Article

References (52)

1. Abadie V, et al. 2005. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106:1843-1850. (Pubitemid 41208603)
2. Ain Q, Sharma S, Garg SK, Khuller GK. 2002. Role of poly[DL-lactideco- glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int. J. Pharm. 239:37- 46.
3. Alsteens D, et al. 2008. Organization of the mycobacterial cell wall: a nanoscale view. Pflugers Arch. Eur. J. Physiol. 456:117-125.
4. Bafica A, et al. 2005. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202:1715-1724. (Pubitemid 41815877)
5. Barry CE, III, Blanchard JS. 2010. The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol. 14:456-466.
6. Behar SM, Divangahi M, Remold HG. 2010. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat. Rev. Microbiol. 8:668-674.
7. Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M. 2009. Fighting tuberculosis: old drugs, new formulations. Expert Opin. Drug Deliv. 6:977-993.
8. Budha NR, Lee RE, Meibohm B. 2008. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr. Med. Chem. 15:809-825. (Pubitemid 351516798)
9. Cooper AM, Mayer-Barber KD, Sher A. 2011. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4:252-260.
10. de Noronha AL, Báfica A, Nogueira L, Barral A, Barral-Netto M. 2008. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol. Res. Pract. 204: 155-161.
11. Dorhoi A, Reece ST, Kaufmann SH. 2011. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol. Rev. 240:235-251.
12. Dutt M, Khuller GK. 2001. Sustained release of isoniazid from a single injectable dose of poly (D,L-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int. J. Antimicrob. Agents 17:115-122. (Pubitemid 32101566)
13. Dye C, Williams BG. 2010. The population dynamics and control of tuberculosis. Science 328:856-861.
14. Egen JG, et al. 2008. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28: 271-284.
15. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. 1989. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55:R1-R4. (Pubitemid 19247505)
16. Gandhi NR, et al. 2010. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843.
17. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control Release 57:171-185. (Pubitemid 29062869)
18. Griffiths G, Nyström B, Sable SB, Khuller GK. 2010. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat. Ver. Microbiol. 8:827- 834.
19. Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47: 833-836. (Pubitemid 36254203)
20. Hearn MJ, et al. 2009. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur. J. Med. Chem. 44:4169-4178.
21. Helke KL, Mankowski JL, Manabe YC. 2006. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis 86:337-348. (Pubitemid 44209336)
22. Hillaireau H, Couvreur P. 2009. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66:2873-2896.
23. Honeybourne D. 1994. Antibiotic penetration into lung tissues. Thorax 49:104-106. (Pubitemid 24115439)
24. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011. The challenge of new drug discovery for tuberculosis. Nature 469:483- 490.
25. Kumar A, Patel G, Menon SK. 2009. Fullerene isoniazid conjugate-a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity. Chem. Biol. Drug Des. 73:553-557.
26. Lambert PA. 2002. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J. Appl. Microbiol. 92(Suppl.):46S-54S. (Pubitemid 34535505)
27. Lawlor C, et al. 2011. Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of M. tuberculosis. Tuberculosis 91:93-97.
28. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. 2010. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev. 62:378-393.
29. Mallipeddi R, Rohan LC. 2010. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomed. 5:533-547.
30. Mehta SK, Kaur G, Bhasin K. 2007. Incorporation of antitubercular drug isoniazid in pharmaceutically microemulsion: effect on microstructure and physical parameters. Pharm. Res. 25:227-236.
31. Mitchison DA. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung. Dis. 4:796-806.
32. Mora-Huertas CE, Fessi H, Elaissari A. 2010. Polymer-based nanocapsules for drug delivery. Int. J. Pharm. 385:113-142.
33. Mshana RN, Tadesse G, Abate G, Miörner H. 1998. Use of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 36:1214-1219. (Pubitemid 28208001)
34. Nathan C, et al. 2008. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis 88(Suppl. 1):S25-S33.
35. Nuermberger E, Grosset J. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255. (Pubitemid 38669936)
36. Pandey R, Zahoor A, Sharma S, Khuller GK. 2003. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83:373-378. (Pubitemid 37464042)
37. Pandey R, Ahmad Z. 2011. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine 7:259-272.
38. Peer D, et al. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2:751-760. (Pubitemid 350223348)
39. Reichman LB, Hershfield ES. 1993. Mycobacterium tuberculosis is particularly susceptible to isoniazid [isonicotinic acid hydrazide (INH)], the most widely used of all antitubercular drugs, p 207-240. In O'Brien J (ed.), Lung biology in health and disease, vol 66. Dekker, New York, NY.
40. Rivers EC, Mansera RL. 2008. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today 13:1090-1098.
41. Russell DG, Barry CE III, Flynn JL. 2010. Tuberculosis: what we don't know can, and does, hurt us. Science 328:852- 856.
42. Schaible UE, Kaufmann SH. 2007. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med. 4:e115.
43. Sharma A, Pandey R, Sharma S, Khuller GK. 2004. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24:599-604. (Pubitemid 39536116)
44. Song X, et al. 2008. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur. J. Pharm. Biopharm. 69:445- 453.
45. Sosnik A, Carcaboso AM, Glisoni RJ. 2010. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 62:547-559.
46. Vandal OH, Nathan CF, Ehrt S. 2009. Acid resistance in Mycobacterium tuberculosis. J. Bacteriol. 191:4714-4721.
47. Verbelen C, et al. 2006. Ethambutol-induced alterations in Mycobacterium bovis BCG imaged by atomic force microscopy. FEMS Microbiol. Lett. 264:192-197. (Pubitemid 44630126)
48. Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. 2008. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 52:3195-3201.
49. World Health Organization. 2011. Global tuberculosis control: WHO reports 2010. World Health Organization, Geneva, Switzerland. http: //whqlibdoc.who.int/publications/2010/9789241564069-eng.pdf.
50. World Health Organization. 2011. Multidrug and extensive drug resistant tuberculosis: 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int /publications/2010/ 9789241599191-eng.pdf.
51. Yadav AB, Misra A. 2007. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity. Antimicrob. Agents Chemother. 51: 3740-3742. (Pubitemid 47519369)
52. Zhao F, et al. 2011. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7:1322-1337.